PRIMARY STUDY
Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.
Key Findings: Cannabidiol selectively reduces croton oil-induced hypermotility in mice in vivo and this effect involves cannabinoid CB1 receptors and FAAH. In view of its low toxicity in humans, cannabidiol may represent a good candidate to normalize motility in patients with inflammatory bowel disease.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Italy
Year of Pub: 2008
Cannabinoids Studied: Cannabidiol (CBD), JWH-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, Fatty Acid Amide Hydrolase (FAAH)
Chemotype: Chemotype III
Receptors Studied: CB1, CB2
Sub-Ratio: 0:1 (THC:CBD)
Dosage: CBD (1–10 mg kg−1) i.p.
Route of Administration: Injection
Link to study
